Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics (NQ: SRPT )

146.02 +0.41 (+0.28%)
Streaming Delayed Price Updated: 11:49 AM EDT, Jul 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 197,449
Open 145.39
Bid (Size) 145.91 (1)
Ask (Size) 146.15 (2)
Prev. Close 145.61
Today's Range 144.34 - 147.33
52wk Range 55.25 - 173.25
Shares Outstanding 93,148,652
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Here's How Much $1000 Invested In Sarepta Therapeutics 10 Years Ago Would Be Worth Today
Via Benzinga
SAVA Stock Plunges as Cassava Sciences CEO Steps Down. What to Know.
The CEO of Cassava Sciences is stepping down, effective immediately. Here's what this means for troubled SAVA stock. 
Via InvestorPlace

Performance

YTD
+51.77%
+51.77%
1 Month
-9.15%
-9.15%
3 Month
+24.85%
+24.85%
6 Month
+20.63%
+20.63%
1 Year
+39.75%
+39.75%

More News

Read More
Jim Cramer Says Don't Sell Match Group: 'You've Just Got A Very, Very Smart Investor In There'
Via Benzinga
Cassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives
From Cassava Sciences, Inc.
Via GlobeNewswire
Here's How Much $100 Invested In Sarepta Therapeutics 10 Years Ago Would Be Worth Today
Via Benzinga
Expert Outlook: Sarepta Therapeutics Through The Eyes Of 25 Analysts
Via Benzinga
Looking At Sarepta Therapeutics's Recent Unusual Options Activity
Via Benzinga
After a Big Win, Is Sarepta Therapeutics Stock a Buy?
Via The Motley Fool
Has Sarepta Therapeutics Become a No-Brainer Stock Buy After This Recent FDA News?
Via The Motley Fool
Exposures Product Safety
1 Soaring Growth Stock to Buy and Hold for 10 Years
Via The Motley Fool
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
Is Pfizer's Pain Sarepta Therapeutics' Gain? Don't Bet on It.
Via The Motley Fool
Here's How Much You Would Have Made Owning Sarepta Therapeutics Stock In The Last 10 Years
Via Benzinga
Sarepta Therapeutics Scores 90-Plus RS Rating On Muscular Dystrophy Approval
Via Investor's Business Daily
Micron To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
DraftKings And Dell Were Among The 10 Biggest Large Cap Stock Gainers Last Week (June 16-June 22): Are These In Your Portfolio?
Via Benzinga
Google Parent Alphabet At All-Time High, In Stock Spotlight: See New Names On IBD 50, Stock Spotlight And More
Via Investor's Business Daily
Growth Stocks Leave Value Stocks In The Dust: 4 Reasons For Biggest Monthly Lead In Over A Year
Via Benzinga
Nasdaq Moves Lower; FactSet Research Posts Upbeat Earnings
Via Benzinga
Why Kaival Brands Innovations Shares Are Trading Lower By 47%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Sarepta's Expanded Approval Unlikely To Influence Novo Holdings' Acquisition of Catalent, But Provides Investor Protection Amid Uncertainty
Via Benzinga
Stocks Stall As Chip Sector Struggles To Rebound; Dollar Eyes 7-Week Peak, Gold, Bitcoin Retreat: What's Driving Markets Friday?
Via Benzinga
Sarepta's Expanded FDA Approval For Elevidys Potentially Shaping Future FDA Reviews, Analyst Says
Via Benzinga
Exposures Product Safety
Gold Down 1%; CarMax Shares Gain After Q1 Earnings
Via Benzinga
Sarepta Therapeutics Stock Soars on FDA Approval
Via MarketBeat
Exposures Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.